Contineum and J&J antidepressant misses key goal in second Phase 2 trial
The oral M1 receptor inhibitor PIPE-307, also known as JNJ-5120, failed to achieve statistically significant results in a mid-stage study for major depressive disorder. This marks the second such failure for the candidate within a year, raising questions about its future development.
PIPE-307, an oral therapy designed to modulate the M1 receptor, was being evaluated as a potential treatment for major depressive disorder. The mid-stage trial failed to produce statistically significant results, meaning the drug did not demonstrate a clear benefit over the control arm on the study's primary measure. The candidate is being developed jointly by Contineum Therapeutics and Johnson & Johnson, with the latter also referencing it as JNJ-5120.
This outcome represents the second consecutive Phase 2 miss for the compound within roughly a year. Consecutive failures at this stage typically prompt sponsors to reassess a program's viability, weighing factors such as the mechanism's biological rationale, trial design issues, and commercial potential. The setback casts uncertainty over the candidate's future, though no formal decision on discontinuation has been indicated.
Patients with major depressive disorder who have not responded to existing treatments could face fewer emerging options if this drug class continues to stumble. For Contineum and Johnson & Johnson, repeated mid-stage failures may force difficult resource-allocation decisions, potentially delaying other pipeline programs. The broader psychiatric drug development field may also take note, as setbacks like this can temper enthusiasm for targeting the M1 receptor, possibly slowing investment in similar mechanisms. Ultimately, the impact hinges on whether these failures reflect the specific compound or the underlying approach itself.